2018
The cost‐effectiveness and budgetary impact of a dolutegravir‐based regimen as first‐line treatment of HIV infection in India
Zheng A, Kumarasamy N, Huang M, Paltiel AD, Mayer KH, Rewari BB, Walensky RP, Freedberg KA. The cost‐effectiveness and budgetary impact of a dolutegravir‐based regimen as first‐line treatment of HIV infection in India. Journal Of The International AIDS Society 2018, 21: e25085. PMID: 29603882, PMCID: PMC5878415, DOI: 10.1002/jia2.25085.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioStandard of careAntiretroviral therapyTenofovir disoproxil fumarateHIV infectionRecent guidelinesFirst-line antiretroviral therapyFirst-line HIV treatmentLifetime incremental cost-effectiveness ratioART-naive patientsDolutegravir-based regimenDTG-based regimenFirst-line treatmentClinical trial dataCost-effectiveness ratioLifetime care costsInitial therapyVirologic suppressionCD4 countHIV diseaseRegimen costsDisoproxil fumarateHIV treatmentAIDS complicationsCare costs
2013
Cost-Effectiveness of HIV Treatment as Prevention in Serodiscordant Couples
Walensky RP, Ross EL, Kumarasamy N, Wood R, Noubary F, Paltiel AD, Nakamura YM, Godbole SV, Panchia R, Sanne I, Weinstein MC, Losina E, Mayer KH, Chen YQ, Wang L, McCauley M, Gamble T, Seage GR, Cohen MS, Freedberg KA. Cost-Effectiveness of HIV Treatment as Prevention in Serodiscordant Couples. New England Journal Of Medicine 2013, 369: 1715-1725. PMID: 24171517, PMCID: PMC3913536, DOI: 10.1056/nejmsa1214720.Peer-Reviewed Original ResearchConceptsEarly antiretroviral therapyHuman immunodeficiency virusAntiretroviral therapySerodiscordant couplesHIV transmissionHIV Prevention Trials Network 052 studyIncremental cost-effectiveness ratioCost-effectiveness ratioResource-limited settingsHIV infectionClinical benefitImmunodeficiency virusHIV treatmentLonger survivalOpportunistic diseasesEarly initiationFive yearsLifetime outcomesPublic healthSuch personsPatientsPeriodTherapyInfectionDisease